Foley Partner David Rosen is quoted in the March 7, 2008 issue of FDA Week on how the FDA is dealing with the backlog of generic drug applications. Rosen, a former generics drug office official, comments that it takes a considerable amount of time to find qualified and efficient people to proficiently review generic drug applications.
People
Related News
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes – 'Technically, it's a third party listening'
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.